Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma

Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, the extensive molecular heterogeneity of the multiple different sarcoma subty...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Rachel J., Perkins, Douglas W., Selfe, Joanna, Kelsey, Anna, Birch, Gavin P., Shipley, Janet M., Schipper, Koen, Isacke, Clare M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890142/
https://www.ncbi.nlm.nih.gov/pubmed/36399638
http://dx.doi.org/10.1158/1535-7163.MCT-22-0312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890142/
https://www.ncbi.nlm.nih.gov/pubmed/36399638
http://dx.doi.org/10.1158/1535-7163.MCT-22-0312

Ejemplares similares